Clinical Trial

STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The investigators hypothesize that patients with mCRC RAS-mutant eligible for a second line treatment with good prognostic features, identified as single metastatic site, long progression free survival (PFS) in first line treatment, might benefit from a personalized approach, with less intensive treatment with regorafenib as part of a continuum-of-care strategy aimed at ensuring quality of life and extending survival.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-10-01.
Status change: Not Yet Recruiting → Recruiting 2025-12-16
Trial Details
NCT Number NCT07213570
Lead Sponsor National Cancer Institute, Naples
Conditions Colorectal Cancer Metastatic
Enrollment 60 participants
Start Date 2025-10-16
Primary Completion 2026-10 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2025-12-17